Tuesday May 13, 2014 0 commentsLOUISVILLE - Silicon Valley-based AntriaBio Inc. (OTCQB: ANTBD), a biopharmaceutical company focused on developing therapeutics for the treatment of diabetes and metabolic disease, announced it has established its primary manufacturing and lab facility in Louisville.
The 27,000-square-foot facility is located just outside Boulder at 1450 Infinite Drive, Louisville. The site will include lab, manufacturing and office space.
AntriaBio said it will move state-of-the-art lab and manufacturing equipment acquired through the acquisition of PR Pharmaceutical's intellectual property and assets in 2013 into the Louisville facility.
AntriaBio's lead product candidate is AB101, an injectable, once-a-week basal insulin for Type 1 and Type 2 diabetes.
The company said its corporate headquarters will remain in Menlo Park.
"Establishing our manufacturing and research presence is an exciting and critical step forward for the company, and we are now poised to work as an integrated team to make clinical material for AB101 and advance that program through the next phase of development," said Nevan Elam, AntriaBio chairman and CEO.